Wattii Health has a longstanding commitment to advancing solutions for patients requiring prosthetic and restorative interventions due to trauma, disease, or congenital conditions. Through the development of assisted and replacement technologies, Wattii identified the need to move beyond mechanical substitution toward biological restoration.
The JARA® 821 platform was developed to support regenerative organ research by integrating insights from large-scale genomic initiatives, including the Human Genome Project (HGP), alongside advances in messenger RNA (mRNA) science. Using autologous tissue samples derived from the patient, the JARA® unit is designed to guide the growth and structuring of living tissue. This approach enables the generation of biologically compatible organs intended to replace damaged or non-functional systems while supporting natural integration with the patient’s body.
The development of JARA® 821 builds on foundational academic research conducted by surgeons Joseph and Charles Vacanti, in collaboration with MIT engineer Bob Langer,whose work explored early methods for cultivating human tissue within controlled laboratory environments. These experiments investigated the use of biological scaffolding techniques to support tissue growth, including highly publicized preclinical models such as the Vacanti Mouse.
Following the publication of this research in the late 1990s, Wattii Health expanded upon these principles to address the global demand for viable organ replacement solutions. The JARA® platform was established to translate regenerative concepts into a scalable, stand-alone system. By combining genomic insights with mRNA-based signaling, the JARA® unit is designed to support organ development tailored to the patient, with the objective of achieving functional compatibility and seamless physiological integration.